Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen. Klicken Sie auf den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.
Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: Wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B. NEAR(hybrid, antrieb, 20)).
Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., leichtbau*, *leichtbau, *leichtbau*).
Interleukin-8 (IL-8/CXCL-8) is a prototype of the ELR+CXC chemokines that play an important role in the promotion and progression of many human cancers including breast cancer. We have recently showed the implication of polymorphism (-251) T/A of IL-8 gene in the susceptibility and prognosis of breast carcinoma. IL-8 acts through its CXCR1 and CXCR2 receptors. CXCR2, expressed on the endothelial cells, is the receptor involved in mediating the angiogenic effects of ELR+CXC chemokines and in particular IL-8.
In the current study, we investigated the susceptibility and prognostic implications of the genetic variation in CXCR2 in breast carcinoma. We also confirmed the implication of IL-8 (-251) T/A polymorphism in a larger cohort. Finally, we combined the IL-8 and CXCR2 variant alleles and analyzed their effects in breast cancer risk and prognosis.
Methods
We used the allele-specific polymerase chain reaction to characterize the variation of IL-8 and CXCR2 for 409 unrelated Tunisian patients with breast carcinoma and 301 healthy control subjects. To estimate the relative risks, Odds ratios and 95% confidence intervals were calculated using unconditional logistic regression after adjusting for the known risk factors for breast cancer. Associations of the genetic marker with the rates of breast carcinoma-specific overall survival and disease-free survival were assessed using univariate and multivariate analyses.
Results
A highly significant association was found between the homozygous CXCR2 (+ 1208) TT genotype (adjusted OR = 2.89; P = 0.008) and breast carcinoma. A significantly increased risk of breast carcinoma was associated with IL-8 (-251) A allele (adjusted OR = 1.86; P = 0.001). The presence of two higher risk genotypes (the TA and TT in IL-8, and the TT in CXCR2) significantly increased the risk of developing breast carcinoma (adjusted OR = 4.15; P = 0.0004).
The CXCR2 (+ 1208) T allele manifested a significant association with an aggressive phenotype of breast carcinoma as defined by a large tumor size, a high histological grade, and auxiliary's lymph node metastasis. A significant association between the IL-8 (-251) A allele and the aggressive form of breast carcinoma was also found.
Moreover, the presence of the IL-8 (-251) A and/or the CXCR2 (+ 1208) T allele showed a significant association with a decreased overall survival and disease-free survival in breast carcinoma patients.
Conclusion
Our results indicated that the polymorphisms in IL-8 and CXCR2 genes are associated with increased breast cancer risk, as well as disease progress, supporting our hypothesis for IL-8 and ELR+CXC chemokine receptor (CXCR2) involvement in breast cancer pathogenesis.
The online version of this article (doi:10.1186/1471-2407-10-283) contains supplementary material, which is available to authorized users.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SK conceived the manuscript, conducted data analysis, and drafted the manuscript. MW contributed to the design and management of data. HK, MF and NB provided samples and clinical information. LC designed and participated in the data analysis and interpretation of the study. AN-H contributed to reviewing the manuscript. All authors read and approved the final manuscript.
Background
Breast cancer is one of the most prevalent cancers in the world. Despite progress made in the last 30 years in breast cancer screening and treatment, this disease is still responsible for almost half a million deaths per year worldwide. Approximately half of diagnosed patients will eventually develop metastatic disease. Treatment for metastatic breast cancer is palliative, and median life expectancy after recurrence is between 24 and 30 months or less [1, 2].
The etiology of breast cancer is extremely complex and, while not yet elucidated, appears to involve numerous genetic, endocrine and external environmental factors. The role of genetic factors in epidemiology and pathogenesis of both sporadic and familial breast cancer is now well established. Only a small minority (~5%) of patients with breast cancer develop the disease as a result of inheritance of germline mutations in dominant, highly penetrant susceptibility genes such as BRCA1 and BRCA2. However, polymorphisms in the genes involved in the complex mechanisms of carcinogenesis may confer low penetrant susceptibility to breast cancer in a significant proportion of the remaining patients [3].
Anzeige
The neoplastic transformation, growth, survival, invasion, and metastases are dependent on the establishment of a pro-angiogenic environment. Local angiogenesis is determined by an imbalance in the over-expression of pro-angiogenic factors, as compared to inhibitors of angiogenesis. The CXC chemokine family is the unique group of cytokines known for their ability to behave in a disparate manner in angiogenesis regulation. Several members of the CXC chemokine are potent promoters of angiogenesis, whereas others inhibit the angiogenic process. The disparity in angiogenic activity among CXC chemokine family members is attributed to three amino acid structural domains at the N terminus, Glu-Leu-Arg (ELR), which is present in angiogenic (i.e., CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8) [4‐6], but not angiostatic (i.e., CXCL4, CXCL9, CXCL10, and CXCL11) CXC chemokines [7].
ELR+ CXC chemokines play an important role in tumor growth and progression in a number of tumor model systems [8]. In particular, interleukin-8 (IL-8/CXCL8), which was originally described as a leukocyte chemoattractant [9], was subsequently found to possess mitogenic and angiogenic properties [10, 11]. Several studies suggested a tendency toward the involvement of IL-8 in cancer development [12]. Elevated IL-8 levels were associated with disease progression and recurrence in human prostate, lung, gastric, and breast cancers [13‐16].
All angiogenic ELR+ CXC chemokines mediate their angiogenic activity through CXCR2 [17]. Subsequent studies have confirmed the expression of CXCR2, not CXCR1, to be the primary functional chemokine receptor in mediating endothelial cell chemotaxis [18, 19]. By considering the expression of IL-8 by breast cancer cells and CXCR2 by large vessel and microvascular endothelial cells [19, 20], an autocrine effect for IL-8 and the chemokine receptor CXCR2 has been suggested.
Promoter regions of a number of cytokine genes contain polymorphisms that directly influence cytokine production [21]. The IL-8 gene is located on chromosome 4q13-21 and consists of four exons, three introns, and a proximal promoter region [22]. Several polymorphisms have been reported in the IL-8 gene. Interestingly, IL-8 production can be controlled by the -251 A/T in the promoter region of this chemokine [23]. Recent data revealed that the IL-8 (-251) A allele is associated with a high expression level of IL-8 protein and a severe neutrophil infiltration [23].Other studies also reported that the IL-8 (-251) T/A polymorphism is associated with a higher risk of developing malignant diseases [24‐27].
Anzeige
Three single polymorphisms at positions +785 C/T, +1208 T/C and +1440 G/A were reported in the CXCR2 gene [28]. Several reports indicated that the polymorphism +1208 C/T which is located in the non-coding region of CXCR2 gene might provide valuable information for the pathogenesis and the susceptibility to chronic inflammatory disease [28, 29].
Previously we have reported an elevated risk for breast cancer among the Tunisian population (n = 308 cases and n = 236 healthy controls) associated with the IL-8 (-251) T/A polymorphism. The implication of this polymorphism in the prognosis of breast carcinoma has also been demonstrated [30].
Based on the abundant evidence for the role of IL-8 and CXCR2 in carcinogenesis, we evaluated in this study the association of CXCR2 (+ 1208) C/T gene polymorphism and breast cancer susceptibility and prognosis in Tunisia. Then we used existing and additional genotype data on 409 breast cancer cases and 301 healthy controls to examine the potential contribution of the combined genotypes of IL-8 and CXCR2 in breast carcinoma occurrence, clinico-pathological characteristics and prognosis.
Methods
Patients and controls
IL-8 and CXCR2 genotype and allele frequencies were determined in a group of 301 control subjects and 409 patients with breast carcinoma. Controls and patients were selected from the same population living in the middle coast of Tunisia and including unrelated subjects.
Data on patient, tumour and treatment characteristics at the study entry for each subject were collected from the department of Radiation Oncology and Medical Oncology of Sousse Hospital (Sousse, Tunisia) between 1996 and 2004. They were selected consecutively whenever practically feasible.
All patients included in this study had primary breast carcinoma, with unilateral breast tumours and with no family history for the disease. The diagnosis of cancer was confirmed by histopathological analyses. The patients (n = 409) had a mean age of 48.0 ± 24.3 (SD) years. At time of analysis, 88 patients experienced recurrence (local or distant). Among them, 56 died from breast carcinoma (63.64%). Table 1 shows the treatment description of all patients. A total of 301 healthy women having a mean age of 48.0 ± 14.9 years, were blood donors with no evidence of any personal or family history of cancer (or other serious illness). Samples from healthy controls were collected consecutively between 1996 and 2004. Control individuals were frequency matched to the expected age distribution of the cases and were from the same geographical area. General characteristics of breast cancer patients and healthy controls women are summarized in Table 1.
Table 1
The general characteristics of breast cancer patients and healthy controls from Tunisian women blood donors
Characteristics, n (%)a
Cases
Controls
P-valueb
Ageb, yr
Mean ± SD
48.0 ± 24.
48.0 ± 14.9
0.97
Body mass index (BMI, kg/m2)
24.1 ± 5.4
20.6 ± 2.5
0.0004
History of benign breast disease
No
241 (58.92)
154 (45.18)
Yes
168 (41.08)
147 (54.82)
0.039
Use of oral contraceptive
No
143 (34.96)
141 (46.84)
Yes
266 (65.04)
160 (53.16)
0.001
a Cases: n = 409; Controls: n = 301. The percentages were shown in the parentheses
b Age and BMI were determined by two-sample t tests; history of benign breast disease and oral contraceptive drugs usage were determined by chi-square tests.
A detailed description of the clinico-pathological characteristics of breast cancer cases has been reported elsewhere [31] and data on tumor size at diagnosis, nodal status and histological grade are briefly included in Table 2.
Table 2
Clinicopathologic Characteristics of the 409 Breast Carcinoma and the Corresponding Univariate Analysis of death (OVS) and Reccurencea (DFS)
Breast carcinoma specific OVS
DFS
Characteristic
%
6-year rate
P-value
6-year rate
P-value
Clinical tumor size
T1-T2
67.08
82.85
70
T3-T4
32.92
62.86
< 0.001
32.86
< 0.000001
Lymph node statusb
N (+)
46.72
84.23
71.43
N (-)
53.28
68.57
< 0.01
44.28
< 0.00001
SBR grading
1-2
60.87
79.28
69.10
3
40.13
57.28
< 0.02
47.80
< 0.01
Age (yrs)
< 50
57.32
78.1
70.0
≥50
42.68
75.71
NS
67.2
NS
OVS: overall survival; DFS: disease free survival; SBR: Scarff, Bloom and Richardson; NS: not significant.
aSix-year survival rates were estimated according to Kaplan and Meier. The log rank test was used to determine whether significant differences (P value) were observed between subgroups of patients.
bDetermined based on the pathologic examination.
Both patients and controls gave their written consent to participate in the study and to allow their biological samples to be genetically analyzed. Approval for the study was given by the National Ethical Committee.
Anzeige
Genomic DNA Extraction
Genomic DNA was extracted from peripheral blood leukocytes by a salting procedure [32]. Briefly, 10 ml of blood was mixed with triton lysis buffer (0.32 M sucrose, 1% Triton X-100, 5 mM MgCl2, H2O, 10 mM Tris-HCl, pH 7.5). Leukocytes were spun down and washed with H2O. The pellet was incubated with proteinase K at 56°C and subsequently salted out at 4°C using a substrate NaCl solution. Precipated proteins were removed by centrifugation. The DNA in supernatant fluid was precipated with ethanol. The DNA pellet was dissolved in 400 μl H2O.
IL-8 (-251) T/A and CXCR2 (+1208) C/T genotyping
An allele-specific polymerase chain reaction (AS-PCR) was used to detect the polymorphisms at positions -251 of IL-8 gene and +1208 of CXCR2 gene. For CXCR2 genotyping, 10 μl of PCR reaction mixture consisting of 50 ng of genomic DNA, 0.01 mM dNTPs, 2 mM MgCl2, 1× Taq polymerase buffer, 0.75 μM of each specific/common primer (Amersham, Paris, France), 0.2 μM of each internal control primer (see Table 3 for primer sequences) and 0.5 U of Taq DNA polymerase (Amersham, Paris, France) were employed. As an internal control, the Beta-globin specific primers were included in the AS-PCR (Table 2). First, a touch-down procedure 25 s at 95°C was carried out. This was followed by annealing for 45 s at temperatures decreasing from 66°C (four cycles) to 60°C (25 cycles) and an extension step at 72°C for 40 s. The genotypes of IL-8 (-251) T/A marker were determined as previously reported [30].
Table 3
Primer sequences used for genotyping of IL-8 (-251) T/A and CXCR2 (+1208) C/T gene polymorphisms (rs 4073 and rs 1801032)
Primer name
Primer sequence
IL-8 (-251) Common
5'-AAT ACG GAG TAT GAC GAA A-3'
IL-8 (-251) T (low expresser)
5'-CTA GAA ATA AAA AAG CAT ACA T-3'
IL-8 (-251) A (high expresser)
5'-CTA GAA ATA AAA AAG CAT ACA A-3'
HGH I CONTROL
5'-GCC TTC CCA ACC ATT CCC TTA-3'
HGH II CONTROL
5'-TCA CGG ATT TCT GTT GTG TTT-3'
CXCR2 (+1208) Common
5'-GTC TTG TGA ATA AGC TGC TAT GA-3'
CXCR2 (+1208) C Allele
5'-CCA TTG TGG TCA CAG GAA GC-3'
CXCR2 (+1208) T Allele
5'-CCA TTG TGG TCA CAG GAA GT-3'
Beta Globin I
5'-ACA CAA CTG TGT TCA CTA-3'
Beta Globin II
5'-CAA CTT CAT CCA CGT TCA CC-3'
HGH I and II primers amplify HGH (human growth hormone) sequence.
The reaction products of IL-8 and CXCR2 gene amplification were loaded onto 2% agarose gel containing ethidium bromide, electrophoresed and visualized under UV transillumination. To ensure quality control of all genotyping results, 25% of randomly selected samples of both cases and controls were analysed a second time, without finding any discrepancies.
Statistical analyses
The genotype and allele frequencies of IL-8 and CXCR2 were tested for the Hardy-Weinberg equilibrium for both patient and control groups using the chi-square test. Two-sample t tests and Chi-square tests were used to explore the bivariate association between the status of breast cancer and other covariates for continuous and categorical variables, respectively. Risk association between the genotypes and breast cancer susceptibility and tumours characteristics was estimated by odds ratio (OR) and 95% confidence intervals (95% CI) using multivariate logistic regression analysis. The model for adjusted OR included age at diagnosis, history of benign breast disease, use of oral contraceptive, and body mass index (BMI).
Anzeige
Disease-free survival (DFS) was defined as the time from the date of diagnosis to the first local or distant recurrence or to last contact. Breast carcinoma-specific overall survival (OVS) was defined as the time from the date of diagnosis to death if the patient died from breast carcinoma or to last contact. Six-year survival rates were estimated, and survival curves were plotted according to Kaplan and Meier [33]. The differences between groups were calculated by the log-rank test [34].
In multivariate analysis, relative risk of recurrence or death from breast carcinoma, 95% confidence intervals, and P values for censored survival data were calculated by use of Cox proportional hazards regression Model [35]. All P value calculations were two-sided, and P value was considered significant at less than 0.05. Only clinicopathologic parameters bearing prognostic significance were included in the Cox model. Clinicopathological parameters were dichotomised as follows: nodal status (≥1 versus no positive lymph node), SBR (Scarff, Bloom and Richardson) tumour grade (1-2 versus 3), clinical tumour size (T1-T2versus T3-T4).
The statistical analysis was performed using SEM-STATISTIQUES software (centre Jean Perrin, Clermont-Ferrand, France).
Results
Polymorphisms in the IL-8 and CXCR2 genes as risk factors for breast carcinoma
The breast cancer patients (n = 409) and healthy controls (n = 301) were all native Tunisian women. The characteristics of the healthy controls and breast cancer patients, including overage ages, body mass index (BMI), history of benign breast disease, and oral contraceptives usage were summarized in Table 1. There were no significant differences between cases and controls concerning age. However, BMI, history of benign breast disease, and oral contraceptives usage were significantly different between cases and controls after the statistical testing (see materials and methods). These confounding factors were adjusted in multivariate logistic regression analysis.
Anzeige
The genotype distribution and allele frequencies for the IL-8 (-251) T/A and CXCR2 (+1208) C/T polymorphisms in all breast carcinoma patients and controls are presented in Table 4. The allele frequencies of IL-8 and CXCR2 genes were in Hardy-Weinberg equilibrium in both patients and controls (P = , P = , P = , P = respectively).
Table 4
The IL-8 (-251) T/A and CXCR2 (+1208) C/T genotype distributions in Control Subjects and in Patients with Breast Carcinoma
Genotypes
Patients (n = 409)
Controls (n = 301)
Crude OR (95% CI)
P-valuea
Adjusted OR (95% CI)b
P-value
n (%)
n (%)
IL-8(-251)T/A
TT
84 (20.5)
92 (30.6)
1
1
TA
201 (49.2)
138 (45.8)
1.60 [1.09-2.34]
0.01
1.71 [1.13-2.55]
0.009
AA
124 (30.3)
71 (23.6)
1.91 [1.24-2.96]
0.002
2.03 [1.56-3.67]
0.001
Alleles
T-allele
369 (45.1)
322 (53.5)
A-allele
449 (54.9)
280 (46.5)
1.40 [1.13-1.74]
0.001
1.86 [1.79-2.45]
0.001
CXCR2(+1208)C/T
CC
195 (46.7)
155 (51.5)
1
1
CT
167 (40.8)
128 (42.5)
1.04 [0.75-1.43]
0.81
1.31 [0.90-1.69]
0.63
TT
47 (11.5)
18 (6.0)
2.08 [1.12-3.88]
0.01
2.89 [1.48-4.55]
0.008
Alleles
C-allele
557 (6.81)
438 (7.28)
T-allele
261 (31.9)
164 (27.2)
1.25 [0.99-1.59]
0.05
1.37 [1.09-1.88]
0.03
aP-value determined by χ2 test.
b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage.
A significantly higher risk for breast cancer was observed for carriers of IL-8 (-251) AA genotype (adjusted Odds Ratio (OR) = 2.03; P = 0.001) and carriers of IL-8 (-251) TA genotype (OR = 1.71; P = 0.009). The IL-8 (-251) A allele was significantly higher in patients compared to controls (OR = 1.86; P = 0.001).
The genotype frequency of the CXCR2 (+1208) TT was 0.115 in patients with breast carcinoma and 0.06 in control subjects (OR = 2.89; P = 0.008). The CXCR2 (+1208) T allele was significantly higher in patients compared to controls (OR = 1.37; P = 0.03) (Table 4).
Because IL-8 functionally interacts with CXCR2 we assessed the effect of multiple genotypes on breast carcinoma risk. Through individual investigations of genotypes, we defined IL-8 (-251) TA, IL-8 (-251) AA, and CXCR2 (+1208) TT as high-risk genotypes.
Anzeige
Table 5 shows the relation between ORs and the number of high-risk genotypes. In controls, there were no high-risk genotypes in 26.91%, 1 in 68.44% and 2 in 4.65%. However, in breast cancer patients, there were no high-risk genotypes in 18.3%, 1 in 71.7% and 2 in 10.02%. The presence of 1 or 2 high-risk genotypes significantly increased the risk of developing breast carcinoma, with ORs of 1.63 (95% CI, 1.13 - 2.59; P = 0.01) and 4.15 (95% CI, 1.92 - 7.32; P = 0.0004), respectively, compared with the absence of the high-risk genotype.
Table 5
Interaction and addictive effects of IL-8 (-251) T/A and CXCR2 (+1208) C/T polymorphisms on breast cancer risk
Genotypes
Patients (n = 409)
Controls (n = 301)
Crude OR (95% CI)
P-valuea
Adjusted OR (95%)b
P-value
IL-8(-251)/CXCR2(+1208)
n %
n %
0
75 (18.34)
81 (26.91)
1
1
1
293 (71.64)
206 (68.44)
1.54 [1.05-2.24]
0.01
1.63 [1.13-2.59]
0.01
2
41 (10.02)
14 (4.65)
3.16 [1.52-6.64]
0.0006
4.15 [1.92-7.32]
0.0004
aP-value determined by χ2 test.
b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage.
The high risk genotypes: IL-8 (-251) T/A = TA/AA; CXCR2 (+1208) C/T = TT
Prognostic significance of polymorphism in IL-8 and CXCR2 genes
Table 2 shows the clinicopathological characterization. The distribution of the clinicopathological markers was in accordance with previously reported data, indicating that our cohort was representative of breast carcinoma patients. Disease-free survival and breast carcinoma-specific OVS rates were estimated and compared by univariate analysis on these clinicopathological parameters. Significant associations were found for clinical tumor size, lymph node status, and tumor grading with DFS and OVS. No significant differences were observed for age.
The distributions of IL-8 and CXCR2 polymorphisms according to the clinico- pathological indices of breast carcinoma severity are presented in Tables 6 and 7. A significant association between IL-8 (-251) A allele and large tumor size (T3-T4), high SBR tumor grade (grade 3), and lymph node metastases was observed (Table 6). In this analysis, we also observed the association of this polymorphism with the hormone status of breast carcinoma. Interestingly, a pronounced association was found between the IL-8 (-251) A allele and a negative hormone status (OR = 1.82; P = 0.0008).
Table 6
Genotype frequencies of IL-8 (-251) T/A polymorphism in relation to pathological indices of Breast Cancer severity
Genotypes
Number of patients (%)
Crude OR (95% CI)
P-valuea
Adjusted OR (95% CI)b
P-value
Clinical tumor size
T1-T2
T3-T4
TT
65 (27.08)
37 (24.51)
1
1
TA
122 (50.84)
58 (38.41)
0.84 [0.49-1.44]
0.48
0.74 [0.67-1.32]
0.87
AA
53 (22.08)
56 (37.08)
1.86 [1.03-3.35]
0.02
1.79 [1.11-3.76]
0.01
Alleles
T-allele
252 (52.50)
132 (43.71)
A-allele
228 (47.50)
170 (56.29)
1.42 [1.05-1.92]
0.01
1.57 [1.32-2.05]
0.01
Lymph nodes status
Negative
Positive
TT
50 (27.62)
42 (19.91)
1
1
TA
92 (50.83)
95 (45.02)
1.46 [0.85-2.52]
0.14
1.32 [0.78-2.01]
0.21
AA
39 (21.55)
74 (35.07)
2.26 [1.24-4.14]
0.004
2.59 [1.47-5.32]
0.002
Alleles
T-allele
192 (53.04)
179 (42.42)
A-allele
170 (46.96)
243 (57.58)
1.53 [1.14-2.05]
0.002
1.58 [1.28-2.24]
0.001
SBR grading
1-2
3
TT
66 (32.19)
46 (28.22)
1
1
TA
111 (54.15)
67 (41.11)
0.87 [0.52-1.45]
0.55
0.91 [0.58-1.49]
0.34
AA
28 (13.66)
50 (30.67)
2.56 [1.35-4.87]
0.001
2.69 [1.52-5.24]
0.0009
Alleles
T-allele
243 (59.27)
159 (48.77)
A-allele
167 (40.73)
167 (51.23)
1.53 [1.13-2.07]
0.004
1.66 [1.38-2.79]
0.002
Estrogen receptor status
Negative
Positive
TT
41 (23.7)
51 (41.13)
1
1
TA
75 (43.35)
44 (35.48)
2.12 [1.17-3.84]
0.007
2.01 [1.32-3.76]
0.006
AA
57 (32.95)
29 (23.39)
2.44 [1.28-4.70]
0.003
2.56 [1.68-4.96]
0.001
Alleles
T-allele
157 (45.38)
146 (58.87)
A-allele
189 (54.62)
102 (41.13)
1.72 [1.22-2.48]
0.001
1.82 [1.96-2.78]
0.0008
aP-value determined by χ2 test.
b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage.
Furthermore, the frequency of the CXCR2 (+1208) T allele was significantly higher in patients with a large tumor size (OR = 1.98; P = 0.0001), with high SBR tumor grade (grade 3) (OR = 1.67; P = 0.01), and with lymph node metastases (OR = 1.83; P = 0.0008). Taken together, these results suggest that the (-251) A allele of the IL-8 gene and the (+1208) T allele of the CXCR2 gene are associated with the aggressive forms of breast carcinoma. No association was found between CXCR2 gene polymorphism and the hormone status of breast cancer patients (Table 7).
Table 7
Genotype frequencies of CXCR2 (+1208) C/T polymorphism in relation to pathological indices of Breast Cancer severity
Genotypes
Number of patients (%)
Crude OR (95% CI)
P-valuea
Adjusted OR (95% CI)b
P-value
Clinical tumor size
T1-T2
T3-T4
CC
117 (48.75)
51 (33.55)
1
1
CT
89 (37.08)
62 (40.79)
1.60 [0.98-2.61]
0.04
1.73 [1.01-2.76]
0.03
TT
34 (14.17)
39 (25.66)
2.63 [1.44-4.82]
0.0006
2.89 [1.64-5.06]
0.0004
Alleles
C-allele
323 (67.29)
164 (53.95)
T-allele
157 (32.71)
140 (46.05)
1.76 [1.29-2.39]
0.0001
1.98 [1.47-2.56]
0.0001
Lymph nodes status
Negative
Positive
CC
94 (51.93)
81 (38.39)
1
1
CT
69 (38.12)
89 (42.18)
1.50 [0.95-2.36]
0.06
1.45 [0.98-2.27]
0.07
TT
18 (9.95)
41 (19.43)
2.64 [1.35-5.21]
0.002
2.72 [1.44-5.43]
0.001
Alleles
C-allele
257 (70.99)
251 (59.48)
T-allele
105 (29.01)
171 (40.52)
1.67 [1.22-2.27]
0.0007
1.83 [1.32-2.46]
0.0008
SBR grading
1-2
3
CC
91 (44.39)
63 (38.18)
1
1
CT
85 (41.46)
64 (38.78)
1.09 [0.67-1.76]
0.71
1.12 [0.78-1.89]
0.65
TT
29 (14.15)
38 (23.03)
1.89 [1.02-3.53]
0.03
1.98 [1.15-3.79]
0.02
Alleles
C-allele
267 (65.12)
190 (57.58)
T-allele
143 (34.88)
140 (42.42)
1.38 [1.01-1.87]
0.03
1.67 [1.08-2.03]
0.01
Estrogen receptor status
Positive
Negative
CC
50 (30.87)
48 (33.33)
1
1
CT
76 (46.91)
60 (41.67)
1.22 [0.70-2.12]
0.46
1.34 [0.78-2.34]
0.35
TT
36 (22.22)
36 (25.00)
0.96 [0.50-1.85]
0.89
0.87 [0.54-1.89]
0.85
Alleles
C-allele
176 (54.32)
156 (54.17)
T-allele
148 (45.68)
132 (45.83)
0.99 [0.71-1.38]
0.96
0.95 [0.66-1.27]
0.87
aP-value determined by χ2 test.
b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage.
Anzeige
When the relationship between the distribution of IL-8 and CXCR2 genotypes in all patients and the survival (OVS and DFS) was tested, significant differences were observed between the OVS and the DFS Kaplan-Meier survival curves for the different polymorphisms.
The breast carcinoma-specific OVS was significantly shorter among patients carrying the IL-8 (-251) A allele (Figure 1A). The estimated 3- and 6-year breast carcinoma-specific OVS rates for the group of patients carrying or not carrying the IL-8 (-251) A allele were respectively 91.4 and 77.1% versus 75.7 and 45.7% (log rank test, P < 0.002). The estimated 3- and 6-year DFS rates in the group of patients with IL-8 (-251) A allele were 81.4% and 50% versus 95.7% and 88.5% in the group of patients without the IL-8 (-251) A allele (log rank test, P < 0.001).
Figure 1
Breast carcinoma-specific overall survival (A) and disease-free survival (B) of 409 breast carcinoma patients according to the presence or absence ofIL-8(-251) A allele (Pdenotes the log-rank test value).
As shown in Figure 2, the breast carcinoma specific OVS and DFS were significantly shorter in the group of patients carrying CXCR2 (+1208) T allele. The estimated 3- and 6-year breast carcinoma OVS rate in the group of patients carrying CXCR2 (+1208) T allele were, respectively, 87.1 and 65.7% versus 95.7% and 90% for those not carrying the (+1208) T allele (log rank test, P < 0.001). The estimated 3- and 6-year DFS rates in the group of patients with CXCR2 (+1208) T allele were 74.3% and 50% versus 90% and 61.4% in the group of patients without the CXCR2 (+1208) T allele (log rank test, P < 0.01).
Figure 2
Breast carcinoma-specific overall survival (C) and disease-free survival (D) of 409 breast carcinoma patients according to the presence or absence ofCXCR2(+1208) T allele (Pdenotes the log-rank test value).
Multivariate analyses were undertaken to evaluate the importance of IL-8 and CXCR2 markers in the recurrence risk and death compared with the clinicopathological parameters. Introducing the genetic and the clinicopathological parameters bearing prognostic significance we tested the Cox model. No genetic and clinicopathological parameters were selected for OVS and DFS.
Further analyses were conducted to explore whether combined high-risk genotypes of the IL-8 and CXCR2 genes were associated with clinicopathological indices and survival among patients. No additional effect was found between the presence of more than one high-risk genotype and indices of an aggressive form of breast carcinoma (nodal status, SBR, tumor grade) or OVS and DFS (data not shown).
Discussion
The ELR+ CXC chemokines play an important role in tumor growth and progression in a number of tumor model systems. IL-8/CXCL8 was the first described angiogenic, mitogenic, and motogenic chemokine in various cancer models and is the prototype of ELR+ CXC chemokines [8, 10‐13]. This chemokine was initially discovered on the basis of its ability to induce mobilization of neutrophils and lymphocytes in vivo [9]. Like the basic fibroblast growth factor (bFGF) and the vascular endothelial growth factor (VEGF), it is a strong angiogenesis inducer. IL-8 mediates endothelial cell chemotaxis and proliferation in vitro and in vivo [36].
The fact that all ELR+CXC chemokines mediate angiogenesis highlights the importance of identifying a common receptor that mediates their biological functions in promoting angiogenesis. The candidate CXC chemokine receptors are CXCR1 and CXCR2. Only CXCL-8/IL-8 and CXCL-6 specifically bind to CXCR1 whereas all ELR+CXC chemokines bind to CXCR2. There is evidence that CXCR2 is implicated in the angiogenic activity of ELR+ CXC chemokines [18, 36].
In recent years, several studies have shown that IL-8 and CXCR2 are overexpressed in a range of human cancers including renal, prostate, pancreatic, colon, nasopharyngeal, and gastric cancers [37‐41]. IL-8 and its receptors were detected on breast tumor cells and endothelial cells of tumor vessels [19‐21]. In addition, IL-8 levels are significantly higher in breast cancer patients compared with healthy controls [42]. Ben-Baruch et al have demonstrated that, aside the role of IL-8 and CXCR2 in mediating the recruitment of the tumor-infiltrating leucocytes to tumor site, their expression may also affect neoplastic proliferation and metastasis [43].
IL-8 and CXCR2 overexpression may present a risk factor in the development and progression of solid tumors. Several polymorphisms have been identified in IL-8 and CXCR2 genes. Among these, IL-8 (-251) T/A polymorphism exerts one of the greatest influences on IL-8 production. Polymorphism +1208 C/T of the CXCR2 gene is implicated in the susceptibility to and the pathogenesis of chronic inflammatory diseases [28, 29].
Recently, we have showed that IL-8 (-251) T/A polymorphism may be a genetic risk factor for breast cancer onset and severity in the Tunisian population [30]. Our current study aims to confirm these results in a larger cohort and to determine whether there is any association between the genetic polymorphism of the CXCR2 and both individual susceptibility to and prognosis of breast carcinoma. Based on the intertwined and interactive roles that IL-8 and CXCR2 play at the molecular level in the angiogenic pathway, we further hypothesized a priori that the joint effect of genetic variants in these angiogenesis regulators may increase breast cancer risk.
In the present study, the comparison of genotype frequencies of IL-8 for breast carcinoma patients and control subjects indicates an increase of IL-8 (-251) TA and AA genotypes. Consequently, the IL-8 (-251) A allele frequency was found to be significantly higher in patients compared with controls. These results confirmed our previous findings in a smaller subset of cases and controls [31].
CXCR2 genotype analysis revealed that carriers of CXCR2 (+1208) TT homozygous genotype are significantly over-represented among breast cancer cases (OR = 2.08; P = 0.01). Despite the great interest in CXCR2 biological properties, little is known about the functional importance of single nucleotide polymorphisms in its gene. This result indicates that CXCR2 gene polymorphism could be considered as a susceptibility gene in breast cancer development.
These findings suggested that individual genetic polymorphisms of IL-8 and CXCR2 were associated with breast carcinoma risk. However, the combination of these genotypes showed a marked association with breast carcinoma risk. We defined the TA and AA genotypes of the IL-8 gene and the TT genotype of the CXCR2 gene as high-risk genotypes according to the individual genotype analysis. Breast carcinoma risk significantly increased according to the number of high-risk genotypes. There was a 63% increase in breast cancer (OR = 1.63; P = 0.01) for the presence of one high-risk genotype. The risk was 4.15 (P = 0.0004) for individuals with two high-risk genotypes. These data, taken together, suggest that there is evidence of a gene-dosage effect.
The assessment of the prognostic value of IL-8 genetic marker in breast carcinoma confirmed the results of our previous study and indicated that IL-8 (-251) A allele is highly associated with aggressive forms of breast carcinoma as defined by large tumor size, high grade and lymph node metastases. In the current study, we also examined for the first time the relationship between IL-8 (-251) T/A polymorphism and the hormonal status. Interestingly, we observed a significant association between IL-8 (-251) A allele and a negative hormonal status (P = 0.0008).
Furthermore, we investigated the association of the CXCR2 (+1208) C/T polymorphism with markers of tumor progression. Our results showed a significant association between CXCR2 (+1208) T allele and a large tumor size (P = 0.0001), high SBR tumor grade (P = 0.01), and lymph node metastases (P = 0.0008). More interestingly, we showed that IL-8 (-251) A and CXCR2 (+1208) T alleles were associated with a shorter overall survival and disease-free survival and, therefore, with a poor prognosis in breast carcinoma.
Given the importance of IL-8 and CXCR2 in angiogenesis, we investigated the relationship between polymorphisms -251 T/A in IL-8 gene and (+1208) C/T in CXCR2 gene and breast carcinoma. The results show that these polymorphisms may be related to breast carcinoma development and progression.
In agreement with our findings, several studies reported a relationship between IL-8 (-251) T/A and CXCR2 (+1208) C/T genes polymorphisms and human cancer. IL-8 (-251) A allele, which resulted in higher IL-8 secretion was associated with an increased risk and poor prognosis of colorectal cancer, prostate cancer, and gastric cancer [24‐26, 44]. Similarly, we reported in a previous study that IL-8 (-251) A allele held a higher risk of nasopharyngeal carcinoma and was highly associated with aggressive forms and poor prognosis [27]. Regarding breast carcinoma, the current study confirmed our previous results obtained in a smaller cohort and is also in agreement with Kamali-Sarvestani et al. who reported that IL-8 (-251) A allele carriers had a significantly higher risk of breast carcinoma than non carriers in the Iranian population [45].
Recently, few studies have shown the relationship between CXCR2 gene polymorphisms and human cancer [46, 47]. The CXCR2 gene polymorphisms were associated with pancreatic cancer but not with prostate and breast cancer [46, 47]. Kamali-Sarvestini et al. have demonstrated that CXCR2 (+1208) C/T polymorphism is not associated with breast cancer [45]. This result is in contrast with our findings.
There is now convincing evidence that these correlations between IL-8 A allele and cancer risk result from an increased level of IL-8 protein, which may have an impact on cancer development and progression via the regulation of immune response and pathways of tumor angiogenesis.
IL-8 is an important chemoattractant that promotes inflammatory processes [9]. The IL-8 receptors CXCR1 and CXCR2 have been reported to be present in a variety of cell types including inflammatory cells, endothelial cells, and fibroblasts [46]. Consequently, IL-8 is a major contributing factor involved in the initiation and amplification of the inflammatory response via its receptors [48]. However, it is known that inflammation profoundly affects the development and progression of tumor and therefore, IL-8 might promote tumor cell proliferation by amplification of inflammation in the tumor microenvironnement via its receptors.
IL-8 proangiogenic effects additionally stem from its ability to inhibit the apoptosis of endothelial cells [49]. This inhibition is associated with increased levels of the anti-apoptotic factors Bcl-xl and Bcl-2 as well as with decreased levels of Bax. It was further shown that IL-8 stimulates increased endothelial cell mRNA expression of matrix metalloproteinases (MMPs) MMP-2 and -9 as well as increases gelatine activity [49]. These MMP activities are required for the proteolytic modifications of basements membranes and extracellular matrices during angiogenesis.
IL-8 was shown to act as an autocrine growth factor and to stimulate invasion and chemotaxis of many tumor cell types. The expression of IL-8 and the receptor of ELR+CXC chemokine CXCR2 in cancer have been evaluated in numerous studies. Overexpression of IL-8 is associated with increasing tumor stage, disease progression and recurrence in human bladder, prostate, breast, lung, gastric, hepatic cancers, and melanoma [11, 14‐16, 43, 50, 51]. Recently, it has been shown that the ER-negative breast cancer cells overexpressed IL-8. Concerning IL-8 receptors, it has been observed that CXCR1 expression was extremely low in breast cancer cells, whereas most of the cells investigated showed a higher expression of CXCR2 [52]. The same study also suggested that IL-8 expression is negatively correlated to ER-status and is expressed preferentially in invasive cancer cells [52]. Moreover, our data showed that the higher percentage of ER-negative tumors were present in patients carrying the IL-8 (-251) A allele which is associated with a higher IL-8 production. Altogether, these results suggested that the genetic variation in the promoter of the IL-8 gene which influences the production of this chemokine could be the genetic basis of the potential tumor progression and invasiveness of breast cancer.
The ability of IL-8 to elicit angiogenic activity depends on the endothelial cell expression of its receptors. Recent studies indicated that CXCR1 and CXCR2 are highly expressed on human microvascular endothelial cells (HMEC) [53]. Antibodies directed at CXCR1 and CXCR2 are capable of inhibiting IL-8 induced migration of HMEC, which indicates that these two receptors are critical for the IL-8 angiogenic response. Since CXCR2 binds to all ELR+CXC chemokines that induce angiogenesis, including IL-8, it may be safe to say that CXCR2 is a mediator of the proangiogenic effects of IL-8.
Several reports have confirmed the importance of CXCR2 in mediating the effects of angiogenesis in human microvascular endothelial cells [18, 36, 53]. Endothelial cells were found to express CXCR2 in vitro and in vivo, but not CXCR1. Blocking the function of CXCR2 by either neutralizing antibodies or inhibiting downstream signalling using specific inhibitors of ERK1/2 and PI3 kinase impaired IL-8-induced stress fiber assembly, chemotaxis, and endothelial tube formation in endothelial cells [39, 54]. Overall, these data strongly support a role for CXCR2 in angiogenesis induced by ELR+CXC chemokines and especially by IL-8.
Conclusion
In summary, our data suggests that IL-8 (-251) T/A and CXCR2 (+1208) C/T polymorphisms are likely to play a major role in susceptibility to and prognosis in breast carcinoma. Although additional studies on a larger scale will be required to confirm and extend our findings, the present data suggest for the first time that CXCR2 (+1208) C/T polymorphism represents a risk factor for poorer prognosis and susceptibility to breast carcinoma. Furthermore, this study provides support for the multigenetic effects of the variant alleles from IL-8, and CXCR2, resulting in a significantly increased risk for breast cancer in the Tunisian population. Our findings also reinforce the role attributed to inflammation, angiogenesis, and their mediators as major contributing factors in the process of breast tumor development, progression and aggressiveness. Using the IL-8 (-251) T/A and CXCR2 (+1208) C/T polymorphisms alone or in combination with other genetic polymorphisms in angiogenic and inflammatory genes to predict breast carcinoma outcome and prognosis may therefore have an important clinical significance.
Acknowledgements
This work is supported by le Ministère de l'Enseignement Supérieur et de la recherche scientifique and by le Ministère de la santé Publique de la République Tunisienne. We would like to thank Mr Adel Rdissi for English revision.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SK conceived the manuscript, conducted data analysis, and drafted the manuscript. MW contributed to the design and management of data. HK, MF and NB provided samples and clinical information. LC designed and participated in the data analysis and interpretation of the study. AN-H contributed to reviewing the manuscript. All authors read and approved the final manuscript.
Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D: Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol. 2001, 21: 1-18. 10.1002/gepi.1014.CrossRefPubMed
4.
Luster AD: Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med. 1998, 338 (7): 436-45. 10.1056/NEJM199802123380706.CrossRefPubMed
Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J: The functionnal role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995, 270: 27348-57. 10.1074/jbc.270.45.27348.CrossRefPubMed
8.
Strieter RM, Belperio JA, Roderick JP, Keane MP: CXC chemokines in angiogenesis of cancer. Semin Cancer Biol. 2004, 14: 195-200. 10.1016/j.semcancer.2003.10.006.CrossRefPubMed
9.
Matsushima K, Baldwin ET, Mukaida N: Interleukin-8 and MCAF: novel leukocyte recruitment and activity cytokines. Chem Immunol. 1992, 51: 236-265. full_text.PubMed
10.
Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CP: IL-8 expression regulates tumorigenecity and metastasis in human bladder cancer. Cancer Res. 2000, 60: 2290-99.PubMed
11.
Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Dinney CPN: Interleukin 8 expression regulates tumorigenecity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000, 6: 2104-19.PubMed
12.
Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001, 2: 375-91. 10.1016/S1359-6101(01)00016-8.CrossRef
13.
Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL: Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007, 67 (14): 6854-62. 10.1158/0008-5472.CAN-07-1162.CrossRefPubMed
14.
Ahmed OI, Adel AM, Diab DR, Gobran NS: Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol. 2006, 13 (2): 61-8.PubMed
15.
Millar HJ, Nemeth JA, McCabe FL, Pikounis B, Wickstrom E: Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model. Cancer Epidemiol Biomarkers Prev. 2008, 17 (8): 2180-87. 10.1158/1055-9965.EPI-07-2915.CrossRefPubMed
16.
Taguchi A, Ohmiya N, Shirai K, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H: Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev. 2005, 14 (11): 2487-93. 10.1158/1055-9965.EPI-05-0326.CrossRefPubMed
17.
Murphy PM: The molecular biology of leucocytes chemoattractant receptors. Annu Rev Immuno. 1994, 12: 593-633. 10.1146/annurev.iy.12.040194.003113.CrossRef
18.
Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM: The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol. 2000, 165 (9): 5269-77.CrossRefPubMed
19.
Murdoch C, Monk PN, Finn A: Chemokine receptor expression on human endothelial cells. Cytokine. 1999, 11: 704-12. 10.1006/cyto.1998.0465.CrossRefPubMed
20.
Miller LJ, Kurtzman SH, Wang Y, Anderson KH, Lindquist RR, Kreutzer DL: Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res. 1998, 18: 77-81.PubMed
Mukaida N, Shiroo M, Matsushima K: Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol. 1989, 143: 1366-71.PubMed
23.
Hull J, Thompson A, Kwiatkowski D: Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax. 2000, 55: 1023-27. 10.1136/thorax.55.12.1023.CrossRefPubMedPubMedCentral
24.
Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H, Gordon MA, Nagashima F, Chang HM, Lenz HJ: Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol. 2008, 19 (10): 1734-41. 10.1093/annonc/mdn368.CrossRefPubMedPubMedCentral
25.
Ohyauchi M, Imatani A, Yonechi M, Asano N, Miura A, Iijima K, Koike T, Sekine H, Ohara S, Shimosegawa T: The polymorphism interleukin 8 -251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut. 2005, 54: 330-35. 10.1136/gut.2003.033050.CrossRefPubMedPubMedCentral
26.
McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM: Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002, 62 (12): 3369-72.PubMed
27.
Ben Nasr H, Chahed K, Mestiri S, Bouaouina N, Snoussi K, Chouchane L: Association of IL-8 (-251) T/A polymorphism with susceptibility to and aggressiveness of nasopharyngeal carcinoma. Hum Immunol. 2007, 68: 761-69. 10.1016/j.humimm.2007.06.006.CrossRefPubMed
28.
Renzoni E, Lympany P, Sestini P: Distribution of novel polymorphisms of IL-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum. 2000, 43: 1633-40. 10.1002/1529-0131(200007)43:7<1633::AID-ANR29>3.0.CO;2-9.CrossRefPubMed
29.
Barnes PJ: Genetics and pulmonary medicine: 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax. 1999, 54: 245-52. 10.1136/thx.54.3.245.CrossRefPubMedPubMedCentral
30.
Snoussi K, Mahfoudh W, Bouaouina N, Helal AN, Chouchane L: Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. Hum Immunol. 2006, 67: 13-21. 10.1016/j.humimm.2006.03.018.CrossRefPubMed
31.
Ben Ahmed S, Aloulou S, Bibi M, Landolsi A, Nouira M, Ben Fatma L, Kallel L, Gharbi O, Khairi H, Kraiem C: Breast cancer detection in Tunisian women: an analysis of a hospital trial involving 729 patients. Santé Publique. 2002, 14: 231-35. 10.3917/spub.023.0231.CrossRefPubMed
32.
Olerup O, Zetterquiest H: HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in two hours: an alternative to serological DR typing in clinical practice including donor recipient matching in cadaveric transplantation. Tissue Antigens. 1992, 39: 225-29. 10.1111/j.1399-0039.1992.tb01940.x.CrossRefPubMed
33.
Kaplan EL, Meir PO: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-61. 10.2307/2281868.CrossRef
34.
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer. 1977, 35: 1-6.CrossRefPubMedPubMedCentral
35.
Cox DR, McCullagh P: Some aspects of analysis of covariance. Biometrics. 1982, 38: 541-61. 10.2307/2530040.CrossRefPubMed
36.
Heidemann J, Ogawa H, Dwinell MB, Rafiee P, Maaser C, Gockel HR: Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR-2. J Biol Chem. 2003, 278: 8508-15. 10.1074/jbc.M208231200.CrossRefPubMed
37.
Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Streiter RM: The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol. 2005, 175 (8): 5351-57.CrossRefPubMed
38.
Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, Montironi R, Waugh DJ: Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res. 2005, 11: 4117-27. 10.1158/1078-0432.CCR-04-1518.CrossRefPubMed
39.
Wente MN, Keane MP, Burdick MD, Friess H, Büchler MW, Ceyhan GO, Reber HA, Strieter RM, Hines OJ: Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett. 2006, 241 (2): 221-7. 10.1016/j.canlet.2005.10.041.CrossRefPubMed
40.
Li A, Varney ML, Singh RK: Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res. 2001, 7 (10): 3298-304.PubMed
41.
Horikawa T, Kaizaki Y, Kato H, Furukawa M, Yoshizaki T: Expression of interleukin-8 receptor A predicts poor outcome in patients with nasopharyngeal carcinoma. Laryngoscope. 2005, 115 (1): 62-7. 10.1097/01.mlg.0000150675.37860.f7.CrossRefPubMed
42.
Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY: Increased serum interleukin-8 patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004, 10: 7157-62. 10.1158/1078-0432.CCR-04-0812.CrossRefPubMed
43.
Ben-Baruch A: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 2003, 5: 31-36. 10.1186/bcr554.CrossRefPubMed
44.
Savage SA, Abnet CC, Mark SD, Qiao YL, Dong ZW, Dawsey SM, Taylor PR, Chanock SJ: Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2004, 13 (12): 2251-57.PubMed
45.
Kamali-Sarvestani E, Aliparasti MR, Atefi S: Association of interleukin-8 (IL-8 or CXCL8) -251T/A and CXCR2 +1208C/T gene polymorphisms with breast cancer. Neoplasma. 2007, 54 (6): 484-9.PubMed
46.
Danahue TR, Hines OJ: CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. World J Surg. 2009, 33 (4): 710-15. 10.1007/s00268-008-9826-z.CrossRef
47.
Yang HP, Woodson K, Taylor PR, Pietinen P, Albanes D, Virtamo J, Tangrea JA: Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer amon Finnish men in a large cancer prevention trial. Eur J Cancer Prev. 2006, 15 (3): 249-53. 10.1097/01.cej.0000199504.07947.e7.CrossRefPubMed
48.
Morohashi H, Miyawaki T, Nomura H, Kuno K, Murakami S, Matsushima K, Mukaida N: Expression of both types of human interleukin-8 receptors on mature neutrophiles, monocytes, and natural killer cells. J Leukoc Biol. 1995, 57: 180-87.PubMed
49.
Li A, Dubey S, Varney ML, Dave BJ, Singh RK: IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003, 170: 3369-76.CrossRefPubMed
50.
Ren Y, Tung-Ping Poon R, Tsui H, Chen WH, Zhi Li, Lau C: Interleukin-8 Serum Levels in Patients with Hepatocellular Carcinoma: Correlations with Clinicopathological Features and Prognosis. Clin Cancer Res. 2003, 9: 5996-6001.PubMed
51.
Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, Lazennec G: IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene. 2003, 22 (2): 256-65. 10.1038/sj.onc.1206113.CrossRefPubMedPubMedCentral
52.
Singh S, Varney M, Singh RK: Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res. 2009, 69 (2): 411-5. 10.1158/0008-5472.CAN-08-3378.CrossRefPubMedPubMedCentral
53.
Salcedo R, Resau JH, Halverson D, Hudson EA, Dambach M, Powell D, Wasserman K, Oppenheim JJ: Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J. 2000, 14 (13): 2055-64. 10.1096/fj.99-0963com.CrossRefPubMed
54.
Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM: Depletion of CXCR-2 Inhibits Tumor Growth and angiogenesis in a murine model of lung cancer. Journal of Immunology. 2004, 172: 2853-2860.CrossRef
Die Prognose beim inflammatorischen Mammakarzinom bleibt ungünstig, wie eine Analyse von US-Registerdaten nahelegt. Ein weiteres Problem ist demnach, dass zunehmend weniger Frauen die leitliniengerechte trimodale Therapie erhalten.
Bei einem nach Radiotherapie lokal rezidivierten Prostatakarzinom sind fokale Salvage-Therapien mit einer guten Prognose verbunden: Das krebsspezifische Zehn-Jahres-Überleben ist einem retrospektiven Vergleich zufolge ebenso hoch wie nach Salvage-Prostatektomie.
Durch Hinzunahme des Glukokortikoid-Rezeptor-Antagonisten Relacorilant zu nab-Paclitaxel wird bei Frauen mit platinresistentem Ovarialkarzinom nicht nur das progressionsfreie, sondern auch das Gesamtüberleben verlängert. Laut finaler Analyse der ROSELLA-Studie gewinnen sie vier Monate an Lebenszeit.
Immunvermittelte Hautreaktionen gehören zu den häufigsten Nebenwirkungen von Immun‑Checkpoint‑Inhibitoren. Eine offene Phase‑2‑Studie untersuchte den JAK‑1‑Inhibitor Upadacitinib bei schwerer ICI‑assoziierter Dermatitis. Die Hautsymptome gingen rasch zurück, schwerwiegende therapieassoziierte Nebenwirkungen wurden nicht beobachtet.
